Supporting these findings, a recent study demonstrated that a farnesoid X receptor agonist, which regulates bile acid homeostasis and cholesterol-derived bile acid biosynthesis, had a beneficial effect on renal outcomes in patients with non-alcoholic steatohepatitis [37]. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.